Skip to main content

Select Drug Profiles

Select Drug Profiles, Payers' Guide

Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

FDA Approvals, In the News, Select Drug Profiles

Nuplazid First Drug Approved for Hallucinations and Delusions Associated with Parkinson’s Disease

FDA Approvals, In the News, Select Drug Profiles

Zynbrita a New Treatment Available for Relapsing Multiple Sclerosis

FDA Approvals, In the News, Select Drug Profiles

FDA Approves First Blood Test to Detect Gene Mutation Associated with Non–Small-Cell Lung Cancer

FDA Approvals, In the News, Select Drug Profiles

FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors

FDA Approvals, Select Drug Profiles

Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer

Lilly Ostrovsky

FDA Approvals, In the News, Select Drug Profiles

Venclexta FDA Approved for Patients with CLL

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Infliximab Biosimilar for Multiple Indications

FDA Approvals, In the News, Select Drug Profiles

FDA Expands Use of Xalkori to Treat Rare Form of Advanced Non-Small Cell Lung Cancer

FDA Approvals, In the News, Select Drug Profiles

FDA Approves First Treatment for Rare Disease in Patients Who Receive Stem Cell Transplant from Blood or Bone Marrow

13
14
15
16
17
18
19

Page 16 of 20
Results 151 - 160 of 200